Literature DB >> 23418396

Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor.

Aline Petrich1, Anika Mann, Andrea Kliewer, Falko Nagel, Anne Strigli, Jan Carlo Märtens, Florian Pöll, Stefan Schulz.   

Abstract

The frequent overexpression of the somatostatin receptors sst2 and sst5 in neuroendocrine tumors provides the molecular basis for therapeutic application of novel multireceptor somatostatin analogs. Although the phosphorylation of the carboxyl-terminal region of the sst2 receptor has been studied in detail, little is known about the agonist-induced regulation of the human sst5 receptor. Here, we have generated phosphosite-specific antibodies for the carboxyl-terminal threonines 333 (T333) and 347 (T347), which enabled us to selectively detect either the T333-phosphorylated or the T347-phosphorylated form of sst5. We show that agonist-mediated phosphorylation occurs at T333, whereas T347 is constitutively phosphorylated in the absence of agonist. We further demonstrate that the multireceptor somatostatin analog pasireotide and the sst5-selective ligand L-817,818 but not octreotide or KE108 were able to promote a detectable T333 phosphorylation. Interestingly, BIM-23268 was the only sst5 agonist that was able to stimulate T333 phosphorylation to the same extent as natural somatostatin. Agonist-induced T333 phosphorylation was dose-dependent and selectively mediated by G protein-coupled receptor kinase 2. Similar to that observed for the sst2 receptor, phosphorylation of sst5 occurred within seconds. However, unlike that seen for the sst2 receptor, dephosphorylation and recycling of sst5 were rapidly completed within minutes. We also identify protein phosphatase 1γ as G protein-coupled receptor phosphatase for the sst5 receptor. Together, we provide direct evidence for agonist-selective phosphorylation of carboxyl-terminal T333. In addition, we identify G protein-coupled receptor kinase 2-mediated phosphorylation and protein phosphatase 1γ-mediated dephosphorylation of T333 as key regulators of rapid internalization and recycling of the human sst5 receptor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418396      PMCID: PMC5416807          DOI: 10.1210/me.2012-1329

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  28 in total

1.  Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells.

Authors:  Christian Doll; Florian Pöll; Kenneth Peuker; Anastasia Loktev; Laura Glück; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Regulation of GPCRs by endocytic membrane trafficking and its potential implications.

Authors:  Aylin C Hanyaloglu; Mark von Zastrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2.

Authors:  Nadder Sharif; Louis Gendron; Julia Wowchuk; Philippe Sarret; Jean Mazella; Alain Beaudet; Thomas Stroh
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

4.  Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.

Authors:  Falko Nagel; Christian Doll; Florian Pöll; Andrea Kliewer; Helmut Schröder; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2011-02-17

5.  Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling.

Authors:  Florian Pöll; Christian Doll; Stefan Schulz
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

6.  Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.

Authors:  S Schulz; S U Pauli; S Schulz; M Händel; K Dietzmann; R Firsching; V Höllt
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Authors:  S Petersenn; J Schopohl; A Barkan; P Mohideen; A Colao; R Abs; A Buchelt; Y-Y Ho; K Hu; A J Farrall; S Melmed; B M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

Review 8.  Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

Authors:  Kjell E Oberg; Jean-Claude Reubi; Dik J Kwekkeboom; Eric P Krenning
Journal:  Gastroenterology       Date:  2010-07-13       Impact factor: 22.682

9.  The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization.

Authors:  N Hukovic; R Panetta; U Kumar; M Rocheville; Y C Patel
Journal:  J Biol Chem       Date:  1998-08-14       Impact factor: 5.157

10.  A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.

Authors:  Andrea Kliewer; Anika Mann; Aline Petrich; Florian Pöll; Stefan Schulz
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

View more
  16 in total

Review 1.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  Differential regulation of somatostatin receptor dephosphorylation by β-arrestin1 and β-arrestin2.

Authors:  Andrea Kliewer; Stefan Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-26       Impact factor: 3.000

3.  Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors.

Authors:  Yona Greenman; Naftali Stern
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

4.  Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.

Authors:  Andreas Lehmann; Andrea Kliewer; Thomas Günther; Falko Nagel; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-04-21

Review 5.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

6.  Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.

Authors:  Erika Tarasco; Petra Seebeck; Svende Pfundstein; Adrian F Daly; Philippe J Eugster; Alan G Harris; Eric Grouzmann; Thomas A Lutz; Christina N Boyle
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

7.  Protein phosphatase modulation of somatostatin receptor signaling in the mouse hippocampus.

Authors:  Sarah J Lucas; David L Armstrong
Journal:  Neuropharmacology       Date:  2015-07-18       Impact factor: 5.250

8.  Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.

Authors:  Anika Mann; Lionel Moulédous; Carine Froment; Patrick R O'Neill; Pooja Dasgupta; Thomas Günther; Gloria Brunori; Brigitte L Kieffer; Lawrence Toll; Michael R Bruchas; Nurulain T Zaveri; Stefan Schulz
Journal:  Sci Signal       Date:  2019-03-26       Impact factor: 8.192

9.  Somatostatin regulates NHE8 protein expression via the ERK1/2 MAPK pathway in DSS-induced colitis mice.

Authors:  Xiao Li; Lin Cai; Hua Xu; Chong Geng; Jing Lu; Liping Tao; Dan Sun; Fayez K Ghishan; Chunhui Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-29       Impact factor: 4.052

Review 10.  Illuminating somatostatin analog action at neuroendocrine tumor receptors.

Authors:  Jean Claude Reubi; Agnes Schonbrunn
Journal:  Trends Pharmacol Sci       Date:  2013-10-31       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.